BioInformant

Your Global Leader in Stem Cell Market Research

Home » iPSC » Page 5

Cynata Therapeutics Secures $6M in Capital Raise, $10M with Payment from FUJIFILM

By Leave a Comment

Cynata Successfully Completes Capital Raising

Cynata TherapeuticsMelbourne, Australia; 23 January 2017: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), has successfully completed a placement of approximately 9.23 million fully-paid ordinary shares at a price of $0.65, for gross proceeds of A$6.0 million before costs (“Placement”). The Placement was made to existing and new sophisticated and institutional investors. Settlement of the Placement, which was heavily over-subscribed, is expected to occur on or about 27 January 2017 with the shares to be issued on 30 January 2017. The Placement shares will be issued under Cynata’s existing placement capacity under Listing Rules 7.1 and 7.1A, and accordingly will not require shareholder approval.  [Read more…]

Is Fate Therapeutics Still Involved with iPS Cells?

By Leave a Comment

Fate TherapeuticsFounded in 2007, by Rudolf Jaenisch, Fate Therapeutics corporate headquarters are located in San Diego, California.  It also has a subsidiary in Ottawa, Canada.

Fate Therapeutics is an innovative biotechnology company developing novel stem cell modulators and biologic or small molecule compounds that guide cell fate.  Fate Therapeutics’ lead clinical program, ProHema, consists of pharmacologically-enhanced hematopoietic stem cells (HSCs) designed to improve HSC support during the normal course of a stem cell transplant for the treatment of patients with hematologic malignancies. [Read more…]

Webinar: iPSC-derived Cell Models for Oncology Applications

By 1 Comment

Human cell models to assess cardiovascular and neurological safety liabilities of cancer drugs

Axiogenesis AG
Webinar Sponsored by Axiogenesis.

Early prediction of drug-induced toxicity is needed in the pharmaceutical and biotechnology industries to decrease late-stage drug attrition.

Specifically, oncology drugs have become more effective in extending the lives of patients suffering from cancer. This improved prognosis, however, is giving more time for anti-cancer drugs to exert toxic effects such as cardiotoxicity, neuropathy and more. [Read more…]

Allen Institute for Cell Science Releases Gene Edited Human Stem Cell Lines

By Leave a Comment

First 5 cell lines in Allen Cell Collection empower the cell science community to explore the dynamic organization of the cell and to better understand health and disease

Allen Institute for Cell ScienceNovember 30, 2016 — The Allen Institute for Cell Science has released the Allen Cell Collection: the first publicly available collection of gene edited, fluorescently tagged human induced pluripotent stem cells that target key cellular structures with unprecedented clarity. Distributed through the Coriell Institute for Medical Research, these powerful tools are a crucial first step toward visualizing the dynamic organization of cells to better understand what makes human cells healthy and what goes wrong in disease.

“Each of our cells—the fundamental units of life—are like a city, with people and resources that move around and factories that generate those resources and carry out important functions,” says Rick Horwitz, Ph.D., Executive Director of the Allen Institute for Cell Science. “With these cell lines, we aim to give the cell science community a kind of live traffic map to see when and where the parts of the cell are with the clarity and consistency they need to make progress toward understanding human health and tackling disease. [Read more…]

Cynata’s “Major Breakthrough” in MSC Manufacturing – Unlimited Quantities, Uniform Batches, Single Donor, & Low Cost

By Leave a Comment

For years, it has been clear that mesenchymal stem cells (MSCs) are a leading type of stem cell being investigated for therapeutic applications, as they have the potential to treat a wide range of acute and degenerative diseases. In addition to secreting factors that can stimulate tissue repair, MSCs can substantially alter their microenvironment, exerting effects that are both anti-inflammatory and anti-fibrotic.

MSCs are also advantageous over other stem cells types, because they avoid the ethical issues that surround embryonic stem cell research and appear to be immuno-privileged. Importantly, MSCs also well-suited for use in the exponential growth area of 3D printing, because of their unusual capacity to form structural tissues. [Read more…]

BioInformant's World-Class Clients